A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Incidence of dose limiting toxicities (DLTs) from the first dose of REGN7945 in combination with linvoseltamab

  Measured over: Up to 21 days

• Incidence of treatment emergent adverse events (TEAEs) during the treatment period with REGN7945 in combination with linvoseltamab

  Measured over: Up to 5 years

• Severity of TEAEs during the treatment period with REGN7945 in combination with linvoseltamab

  Measured over: Up to 5 years

• Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination therapy

  Measured over: Within 12 weeks of starting cycle 1

• VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapy

  Measured over: Within 12 weeks of starting cycle 1

• Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination therapy

  Measured over: Within 12 weeks of starting cycle 1

• PR or better as determined by the investigator using the IMWG response criteria in patients receiving linvoseltamab monotherapy

  Measured over: Within 12 weeks of starting cycle 1

Changes Tremor has spotted